You are here

  • Home
  • Archive
  • Volume 7, Issue 6
  • Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol

Citation Tools

Article menu

Download PDFPDF

XML
Gastroenterology and hepatology
Protocol
Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Arndtz K, Corrigan M, Rowe A on behalf of the BUTEO trial team, et al
Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol
BMJ Open 2017;7:e015081. doi: 10.1136/bmjopen-2016-015081